Radiosensitization of rat glioma with bromodeoxycytidine and adenovirus expressing herpes simplex virus-thymidine kinase delivered by slow, rate- controlled positive pressure infusion

David Brust, Jeffrey Feden, Julie Farnsworth, Cyrus Amir, William C. Broaddus, Kristoffer Valerie

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Infection of rat RT2 glioma cells in vitro with an adenovirus (ADV-TK) expressing herpes simplex virus (HSV) thymidine kinase (TK) and subsequent exposure to 5-bromo-2'-deoxycytidine (BrdC), which is specifically incorporated into ADV-TK-infected cell DNA as 5-bromo-2'-deoxyuridine (BrdU), results in significant radiosensitization (sensitizer enhancement ratio: 1.4- 2.3) compared with Adβgal-infected cells. Cell killing correlated well with increased BrdU DNA incorporation and with apoptosis. Whereas radiation (4 Gy) alone was relatively ineffective in inducing apoptosis, treatment with HSV- TK/BrdC resulted in BrdC dose- (10-100 μM) and time-dependent (24-48 hours) increases, and the combination of the two treatments produced a synergistic response (1.5- to 2-fold). To investigate the effects of the ADV-TK/BrdC treatment in vivo, RT2 cells were grown as soft tissue tumors in Fischer 344 rats and conditions for virus infusion were optimized by altering the volume and rate of infusion using a rate-controlled positive pressure device. We found that relatively large volumes (100-150 μL) of virus delivered at rates of ≤ μL/minute were optimal and gave uniform and reproducible results. Using these optimal infusion conditions, we were able to achieve 40% adenovirus infection in the tumor. Infection of RT2 tumors with ADV-TK and continuous administration of BrdG from an osmotic pump resulted in significant (.001 < P< .009) tumor regression 6 days after radiation (30 Gy delivered as 2 x 5 Gy over 3 days) compared with controls. In situ staining of sectioned tumors with anti-BrdU antibody or by high-performance liquid chromatography analysis of extracted and hydrolyzed tumor DNA confirmed that we obtained efficient and specific incorporation of BrdU into tumor cells. These results suggest that adenovirus mediated delivery of HSV-TK in combination with BrdC and radiation can potentially be an efficient combination modality for the treatment of gliomas.

Original languageEnglish (US)
Pages (from-to)778-788
Number of pages11
JournalCancer gene therapy
Volume7
Issue number5
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Bromodeoxycytidine
Thymidine Kinase
Simplexvirus
Adenoviridae
Glioma
Deoxycytidine
Pressure
Deoxyuridine
Neoplasms
Radiation Dosage
DNA
Apoptosis
Adenoviridae Infections
Parvovirus
Inbred F344 Rats
Bromodeoxyuridine
Infection
High Pressure Liquid Chromatography
Radiation
Staining and Labeling

Keywords

  • Cancer gene therapy
  • Drug delivery
  • Halogenated pyrimidines
  • Osmotic pump
  • Radiation

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Radiosensitization of rat glioma with bromodeoxycytidine and adenovirus expressing herpes simplex virus-thymidine kinase delivered by slow, rate- controlled positive pressure infusion. / Brust, David; Feden, Jeffrey; Farnsworth, Julie; Amir, Cyrus; Broaddus, William C.; Valerie, Kristoffer.

In: Cancer gene therapy, Vol. 7, No. 5, 01.01.2000, p. 778-788.

Research output: Contribution to journalArticle

@article{27734027a94e4ccf9e922c853280e562,
title = "Radiosensitization of rat glioma with bromodeoxycytidine and adenovirus expressing herpes simplex virus-thymidine kinase delivered by slow, rate- controlled positive pressure infusion",
abstract = "Infection of rat RT2 glioma cells in vitro with an adenovirus (ADV-TK) expressing herpes simplex virus (HSV) thymidine kinase (TK) and subsequent exposure to 5-bromo-2'-deoxycytidine (BrdC), which is specifically incorporated into ADV-TK-infected cell DNA as 5-bromo-2'-deoxyuridine (BrdU), results in significant radiosensitization (sensitizer enhancement ratio: 1.4- 2.3) compared with Adβgal-infected cells. Cell killing correlated well with increased BrdU DNA incorporation and with apoptosis. Whereas radiation (4 Gy) alone was relatively ineffective in inducing apoptosis, treatment with HSV- TK/BrdC resulted in BrdC dose- (10-100 μM) and time-dependent (24-48 hours) increases, and the combination of the two treatments produced a synergistic response (1.5- to 2-fold). To investigate the effects of the ADV-TK/BrdC treatment in vivo, RT2 cells were grown as soft tissue tumors in Fischer 344 rats and conditions for virus infusion were optimized by altering the volume and rate of infusion using a rate-controlled positive pressure device. We found that relatively large volumes (100-150 μL) of virus delivered at rates of ≤ μL/minute were optimal and gave uniform and reproducible results. Using these optimal infusion conditions, we were able to achieve 40{\%} adenovirus infection in the tumor. Infection of RT2 tumors with ADV-TK and continuous administration of BrdG from an osmotic pump resulted in significant (.001 < P< .009) tumor regression 6 days after radiation (30 Gy delivered as 2 x 5 Gy over 3 days) compared with controls. In situ staining of sectioned tumors with anti-BrdU antibody or by high-performance liquid chromatography analysis of extracted and hydrolyzed tumor DNA confirmed that we obtained efficient and specific incorporation of BrdU into tumor cells. These results suggest that adenovirus mediated delivery of HSV-TK in combination with BrdC and radiation can potentially be an efficient combination modality for the treatment of gliomas.",
keywords = "Cancer gene therapy, Drug delivery, Halogenated pyrimidines, Osmotic pump, Radiation",
author = "David Brust and Jeffrey Feden and Julie Farnsworth and Cyrus Amir and Broaddus, {William C.} and Kristoffer Valerie",
year = "2000",
month = "1",
day = "1",
doi = "10.1038/sj.cgt.7700168",
language = "English (US)",
volume = "7",
pages = "778--788",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Radiosensitization of rat glioma with bromodeoxycytidine and adenovirus expressing herpes simplex virus-thymidine kinase delivered by slow, rate- controlled positive pressure infusion

AU - Brust, David

AU - Feden, Jeffrey

AU - Farnsworth, Julie

AU - Amir, Cyrus

AU - Broaddus, William C.

AU - Valerie, Kristoffer

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Infection of rat RT2 glioma cells in vitro with an adenovirus (ADV-TK) expressing herpes simplex virus (HSV) thymidine kinase (TK) and subsequent exposure to 5-bromo-2'-deoxycytidine (BrdC), which is specifically incorporated into ADV-TK-infected cell DNA as 5-bromo-2'-deoxyuridine (BrdU), results in significant radiosensitization (sensitizer enhancement ratio: 1.4- 2.3) compared with Adβgal-infected cells. Cell killing correlated well with increased BrdU DNA incorporation and with apoptosis. Whereas radiation (4 Gy) alone was relatively ineffective in inducing apoptosis, treatment with HSV- TK/BrdC resulted in BrdC dose- (10-100 μM) and time-dependent (24-48 hours) increases, and the combination of the two treatments produced a synergistic response (1.5- to 2-fold). To investigate the effects of the ADV-TK/BrdC treatment in vivo, RT2 cells were grown as soft tissue tumors in Fischer 344 rats and conditions for virus infusion were optimized by altering the volume and rate of infusion using a rate-controlled positive pressure device. We found that relatively large volumes (100-150 μL) of virus delivered at rates of ≤ μL/minute were optimal and gave uniform and reproducible results. Using these optimal infusion conditions, we were able to achieve 40% adenovirus infection in the tumor. Infection of RT2 tumors with ADV-TK and continuous administration of BrdG from an osmotic pump resulted in significant (.001 < P< .009) tumor regression 6 days after radiation (30 Gy delivered as 2 x 5 Gy over 3 days) compared with controls. In situ staining of sectioned tumors with anti-BrdU antibody or by high-performance liquid chromatography analysis of extracted and hydrolyzed tumor DNA confirmed that we obtained efficient and specific incorporation of BrdU into tumor cells. These results suggest that adenovirus mediated delivery of HSV-TK in combination with BrdC and radiation can potentially be an efficient combination modality for the treatment of gliomas.

AB - Infection of rat RT2 glioma cells in vitro with an adenovirus (ADV-TK) expressing herpes simplex virus (HSV) thymidine kinase (TK) and subsequent exposure to 5-bromo-2'-deoxycytidine (BrdC), which is specifically incorporated into ADV-TK-infected cell DNA as 5-bromo-2'-deoxyuridine (BrdU), results in significant radiosensitization (sensitizer enhancement ratio: 1.4- 2.3) compared with Adβgal-infected cells. Cell killing correlated well with increased BrdU DNA incorporation and with apoptosis. Whereas radiation (4 Gy) alone was relatively ineffective in inducing apoptosis, treatment with HSV- TK/BrdC resulted in BrdC dose- (10-100 μM) and time-dependent (24-48 hours) increases, and the combination of the two treatments produced a synergistic response (1.5- to 2-fold). To investigate the effects of the ADV-TK/BrdC treatment in vivo, RT2 cells were grown as soft tissue tumors in Fischer 344 rats and conditions for virus infusion were optimized by altering the volume and rate of infusion using a rate-controlled positive pressure device. We found that relatively large volumes (100-150 μL) of virus delivered at rates of ≤ μL/minute were optimal and gave uniform and reproducible results. Using these optimal infusion conditions, we were able to achieve 40% adenovirus infection in the tumor. Infection of RT2 tumors with ADV-TK and continuous administration of BrdG from an osmotic pump resulted in significant (.001 < P< .009) tumor regression 6 days after radiation (30 Gy delivered as 2 x 5 Gy over 3 days) compared with controls. In situ staining of sectioned tumors with anti-BrdU antibody or by high-performance liquid chromatography analysis of extracted and hydrolyzed tumor DNA confirmed that we obtained efficient and specific incorporation of BrdU into tumor cells. These results suggest that adenovirus mediated delivery of HSV-TK in combination with BrdC and radiation can potentially be an efficient combination modality for the treatment of gliomas.

KW - Cancer gene therapy

KW - Drug delivery

KW - Halogenated pyrimidines

KW - Osmotic pump

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=0034077052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034077052&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700168

DO - 10.1038/sj.cgt.7700168

M3 - Article

VL - 7

SP - 778

EP - 788

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 5

ER -